Independent variables | N (%) | Anti-SARS-CoV-2 positivity | Past infection | Recent infection | Univariate analysis | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
No (%) | Yes (%) | p-value* | No (%) | Yes (%) | p-value* | No (%) | Yes (%) | p-value* | OR (95% CI) | p-value | ||
ABO blood group | ||||||||||||
A | 61 (17.8) | 57 (93.4) | 4 (6.6) | 0.075 | 59 (96.7) | 2 (3.3) | 0.023 | 59 (96.7) | 2 (3.3) | 0.174 | 2.12 (0.60–7.48) | 0.245 |
B | 54 (15.7) | 51 (94.4) | 3 (5.6) | 53 (98.1) | 1 (1.9) | 52 (96.3) | 2 (3.7) | 1.77 (0.44–7.10) | 0.418 | |||
AB | 10 (2.9) | 8 (80.0) | 2 (20.0) | 8 (80.0) | 2 (20.0) | 10 (100) | 0 (0.0) | 7.54 (1.35–42.2) | 0.022 | |||
O | 218 (63.6) | 211 (96.8) | 7 (3.2) | 212 (97.2) | 6 (2.8) | 217 (99.5) | 1 (0.5) | 1.00 | – | |||
RH blood group | ||||||||||||
RH– | 9 (2.6) | 8 (88.9) | 1 (11.1) | 0.353 | 9 (100) | 0 (0.0) | 0.580 | 8 (88.9) | 1 (11.1) | 0.014 | 2.66 (0.31–22.7) | 0.371 |
RH + | 334 (97.4) | 319 (95.5) | 15 (4.5) | 323 (96.7) | 11 (3.3) | 330 (98.8) | 4 (1.2) | 1.00 | – | |||
ABO/RH blood group | ||||||||||||
ARh + | 58 (16.9) | 55 (94.8) | 3 (5.2) | 0.033 | 56 (96.6) | 2 (3.4) | 0.081 | 57 (98.3) | 1 (1.7) | < 0.001 | 1.00 | – |
ARh– | 3 (0.9) | 2 (66.7) | 1 (33.3) | 3 (100) | 0 (0.0) | 2 (66.7) | 1 (33.3) | 9.17 (0.64–132) | 0.103 | |||
BRh + | 54 (15.7) | 51 (94.4) | 3 (5.6) | 53 (98.1) | 1 (1.9) | 52 (96.3) | 2 (3.7) | 1.08 (0.21–5.59) | 0.928 | |||
BRh– | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | – | – | |||
ABRh + | 10 (2.9) | 8 (80.0) | 2 (20.0) | 8 (80.0) | 2 (20.0) | 10 (100) | 0 (0.0) | 4.58 (0.66–31.8) | 0.123 | |||
ABRh– | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | – | – | |||
ORh + | 212 (61.8) | 205 (96.7) | 7 (3.3) | 206 (97.2) | 6 (2.8) | 211 (99.5) | 1 (0.5) | 0.63 (0.16–2.50) | 0.507 | |||
ORh– | 6 (1.7) | 6 (100) | 0 (0.0) | 6 (100) | 0 (0.0) | 6 (100) | 0 (0.0) | 0 (0.0–0.0) | 0.999 |